Silver Book Fact

For beneficiaries with wet age-related macular degeneration (AMD), annual Medicare part B payments for vision care increased from $1,504 per beneficiary in 1994 to $3,263 in 2006–due in large part to anti-VEGF treatments.

Day S, Acquah K, Lee P, Mruthyunjaya P, et al. Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994-2007. Ophthalmol. 2011; 152(6): 1014-20. http://www.ajo.com/article/S0002-9394%2811%2900410-7/abstract

Reference

Title
Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994-2007
Publication
Ophthalmol
Publication Date
2011
Authors
Day S, Acquah K, Lee P, Mruthyunjaya P, et al.
Volume & Issue
Volume 152, Issue 6
Pages
1014-20
URL
Read Full Resource

Categories

  • Cost of Disease
  • Economic Burden

Related Facts

  • A study of glaucoma patients found that compared with control subjects, they were over 3 times more likely to have fallen in the previous year, over 6 times more likely…  
  • An estimated 424,801 more visually impaired and blind individuals live in nursing homes than would be expected if they had normal vision.  
  • Glaucoma is one of the leading causes of blindness among age-related eye diseases in Hispanic persons– accounting for 28.6% of cases of blindness.  
  • An estimated 6.5% of Americans age 40 and older have age-related macular degeneration (AMD).  
  • Visual loss from subfoveal choroidal neovascularization, a characteristic of wet age-related macular degeneration (AMD), was found to have a profound impact on how patients felt about their health-related quality of…